OPER Technology Limited aims to develop biomedical technologies orienting precision medicine, regenerative medicine and personalised therapy; also, targeting incurable diseases. It is currently a member company of Incu-Bio Programme of Hong Kong Science and Technology Parks Corporation. Its technologies have been granted 4 US patents and have their patent applications filed in China and the EU. Its core and patented technology – Autologous Neural Stem Cell (ANSc) Harvest, potentiates in individualised cell replacement therapy for neurodegenerative disease patients. Since establishment, the company has won 26 local and international awards, for example First Runner-up (Entrepreneurial Group) in the 5th China innovation and Entrepreneurship Competition (Hong Kong, Macau and Taiwan), for its state-of-the-art technologies and significance in the industry.
